Corus製藥控股 CRBP 深 滬
等待開盤 08-30 09:30:00 美东时间
9.37
-0.530
-5.35%
華盛通- 最 高9.98
- 今 開9.98
- 成交量 9.04万股
- 最 低 9.35
- 昨 收 9.90
- 總市值 1.15亿
- 52周最高 56.93
- 市盈率 靜 --
- 換手率 0.74%
- 52周最低 4.64
- 委 比 46.70%
- 總股本 1223.68万
- 歷史最高 323.40
- 量 比 0.73
- 振 幅 6.36%
- 歷史最低 3.00
- 每 手 1
- 風險率 11.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What Most Traders Miss When The Market Starts To Crack
On Wednesday, I showed you why we've officially entered one of the most dangero...
08-22 03:38
Corbus Pharmaceuticals Q2 EPS $(1.44) Beats $(1.52) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.52) by 5.39 percent. This is a 60 percent decrease over losses of $(0.90) per share
08-05 20:36
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals provided updates on its three clinical programs (CRB-701, CRB-913, and CRB-601), with data expected in the second half of 2025. CRB-701, targeting Nectin-4, will present Phase 1/2 dose expansion data at ESMO 2025. CRB-913, an obesity drug, initiated its MAD study and shows no neuropsychiatric events. CRB-601 is progressing in Phase 1. The company reported a Q2 2025 net loss of $17.7M, up due to increased R&D expenses, with ...
08-05 12:00
Corbus Pharmaceuticals Announces That An Abstract On Updated Clinical Data From Its Phase 1/2 Clinical Study Of CRB-701 Has Been Accepted For Presentation As A Poster At The European Society For Medical Oncology Congress 2025, October 17-21, 2025 In Berlin, Germany
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the
07-30 20:02
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
Corbus Pharmaceuticals announced that updated clinical data for CRB-701 (SYS6002) from its Phase 1/2 study has been accepted for presentation at the 2025 ESMO Congress in Berlin. The study evaluates the safety, pharmacokinetics, and efficacy of CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate, in patients with solid tumors. Part A dose escalation assessed four doses, with ongoing dose optimization and expansion in HNSCC, cerv...
07-30 12:00
朱嘉明：稳定币的深层逻辑与未来图景
朱嘉明在“稳定币的未来”研讨会上分析了稳定币的历史演变及其对现代货币制度的影响。他认为稳定币可分为古典和现代两个阶段，古典稳定币基于贵金属或美元与黄金挂钩，而现代稳定币则结合区块链技术，分为抵押型和算法型。稳定币作为加密货币扩张的必然产物，正在重塑货币理论及数字经济格局。朱嘉明指出，美国正构建以比特币、稳定币和相关法案为核心的“三位一体”平行货币体系，而中国需探索央行数字货币与稳定币的协同路径。稳定币不仅提升美元竞争力，也为普惠金融提供了创新工具。
07-24 13:54
GENIUS 法案落地 我们该如何审慎对待稳定币叙事？
美国众议院通过三项加密相关立法，其中GENIUS法案即将生效，标志美国首次为稳定币确立国家级监管框架。全球主要经济体加速合规框架设计，稳定币从加密圈边缘议题跃升为国家战略重点。稳定币市场长期由USDT和USDC主导，新兴项目如PayPal和USD1推动其职能扩展至Web2和实体经济场景。合规要求增加，未来增长潜力在于替代传统美元账户。稳定币发展将牵动货币主权和地缘秩序，成为国际博弈焦点。
07-21 14:15
Genius 法案落地：我们该如何审慎对待稳定币叙事
美国众议院通过三项加密法案，GENIUS法案即将生效。稳定币迎来国家级监管框架，迈向主流金融体系，全球主要经济体加速立法支持。美国放弃CBDC，扶持私营稳定币，将影响全球监管设计。市场规模增长，USDT和USDC主导，新兴项目拓展应用场景。合规要求增加，稳定币面临进入Web2和实体经济的挑战，未来潜力巨大但需应对复杂博弈。货币发行的权力属性意味着稳定币将进一步影响地缘经济格局。
07-18 11:17
Cannabis Stock Gainers And Losers From July 16, 2025
GAINERS: 4Front Ventures (OTC:FFNTF) shares closed up 33.33% at $0.00 Blueberr...
07-17 04:32
【美股盤前】川普的巴西關稅政治化！達美航空漲12%，因螞蟻支持穩定幣Circle升4%，台積電二季度營收超預期，稀土股MP暴漲
TradingKey - 7月10日週四美股盤前，比特幣和輝達股價創新高之後，投資人權衡川普對巴西征收高達50%關稅和關稅政治化影響，標普500指數和納指100期貨盤前走平。達美航空恢復全年業績指引，預告本季和全年利潤高於預期打破市場對航空股擔憂，達美航空盤前大漲12%，帶動美國航空、阿拉斯加航空上漲4%，多個航空股走高。MP Materials與五角大樓達成數十億美元協議，MP大漲40%，帶動稀土概念股上揚。
07-10 12:19
